Literature DB >> 30242308

Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening.

Soo Jeong Kim1, Andrew J Vickers2, Jim C Hu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30242308      PMCID： PMC6719541          DOI： 10.1001/jamaoncol.2018.4160

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  7 in total

1.  Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.

Authors:  Nina Klemann; M Andreas Røder; J Thomas Helgstrand; Klaus Brasso; Birgitte G Toft; Ben Vainer; Peter Iversen
Journal:  Lancet Oncol       Date:  2017-01-14       Impact factor: 41.316

Review 2.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Authors:  Paul C Moldovan; Thomas Van den Broeck; Richard Sylvester; Lorenzo Marconi; Joaquim Bellmunt; Roderick C N van den Bergh; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Theo H van der Kwast; Vsevolod B Matveev; Henk G van der Poel; Maria De Santis; Ivo G Schoots; Thomas Wiegel; Cathy Yuhong Yuan; Philip Cornford; Nicolas Mottet; Thomas B Lam; Olivier Rouvière
Journal:  Eur Urol       Date:  2017-03-21       Impact factor: 20.096

3.  Prostate MRI: access to and current practice of prostate MRI in the United States.

Authors:  James L Leake; Rulon Hardman; Vijayanadh Ojili; Ian Thompson; Alampady Shanbhogue; Javier Hernandez; Jelle Barentsz
Journal:  J Am Coll Radiol       Date:  2014-01-02       Impact factor: 5.532

4.  Projections of the cost of cancer care in the United States: 2010-2020.

Authors:  Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2011-01-12       Impact factor: 13.506

5.  The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Authors:  Andrew J Vickers; James A Eastham; Peter T Scardino; Hans Lilja
Journal:  Urology       Date:  2016-02-02       Impact factor: 2.649

6.  Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.

Authors:  Nienke L Hansen; Brendan C Koo; Ferdia A Gallagher; Anne Y Warren; Andrew Doble; Vincent Gnanapragasam; Ola Bratt; Christof Kastner; Tristan Barrett
Journal:  Eur Radiol       Date:  2016-10-24       Impact factor: 5.315

7.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079
  7 in total
  6 in total

1.  A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.

Authors:  Lars Boesen; Frederik B Thomsen; Nis Nørgaard; Vibeke Løgager; Ingegerd Balslev; Rasmus Bisbjerg; Henrik S Thomsen; Henrik Jakobsen
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-04-15       Impact factor: 5.554

2.  A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.

Authors:  Samuel Carbunaru; Oluwarotimi S Nettey; Pooja Gogana; Irene B Helenowski; Borko Jovanovic; Maria Ruden; Courtney M P Hollowell; Roohollah Sharifi; Rick A Kittles; Edward Schaeffer; Peter Gann; Adam B Murphy
Journal:  BMC Urol       Date:  2019-11-27       Impact factor: 2.264

Review 3.  Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?

Authors:  Edward K Chang; Adam J Gadzinski; Yaw A Nyame
Journal:  Asian J Urol       Date:  2021-06-23

Review 4.  PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE.

Authors:  Igor Tomašković; Sven Nikles; Miroslav Tomić; Ivan Pezelj; Boris Ružić
Journal:  Acta Clin Croat       Date:  2019-11       Impact factor: 0.780

5.  Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions.

Authors:  Michael D Gross; Bashir Al Hussein Al Awamlh; Jonathan E Shoag; Elizabeth Mauer; Samprit Banerjee; Daniel J Margolis; Juan M Mosquera; Ann S Hamilton; Maria J Schumura; Jim C Hu
Journal:  BMJ Surg Interv Health Technol       Date:  2019-08-23

6.  Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients.

Authors:  Luke L Wang; Brandon L Henslee; Peter B Sam; Chad A LaGrange; Shawna L Boyle
Journal:  Prostate Cancer       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.